Abstract 421P
Background
Tumors deficient in DNA repair mechanism, particularly the HRR including BRCA (somatic and /or germline ) are sensitive to Platinum chemotherapy, PARP inhibitors (PARPi), and immunotherapy (IO) in cancers like breast and ovarian, however, clinical trials are ongoing in pancreatic, prostate, endometrial and other cancer types which have progressed on first-line chemotherapy. In this study, CGP identified the landscape of sBRCA and HRR as potential biomarkers across the multi-cancer cohort.
Methods
950 biopsy proven patient samples at HCG were profiled using Illumina TruSight Oncology 500 assay on NextSeq2000 in an IRB-approved study. Sequenced data was processed by StrandOmics platform.
Results
About 142 (15 %) patients in the studied cohort of multiple cancer types were found with alterations in sBRCA and HRR pathway. 208 mutations were detected across 950 cases with 66 cases reporting ≥ 1 HRR gene alterations (mean incidence of 1.4/case). 37 HRR cases were associated with elevated tumor mutation burden. sBRCA1 and sBRCA2 were found in 22 and 27 patients respectively accounting for 3% HRR pathway. Other HRR genes included ATM, RAD51, PTEN, ATRX, PALB2, MRE11A, RAD50, CDK12, ARID1A and PTEN in 12 % of HRR pathway. It is noteworthy that sBRCA and HRR gene alterations were found across diverse cancers, highest in gastrointestinal followed by breast cancer (TNBC-56%) (Table). Apart from FDA approved cancers (n=57), HRR alteration were prevalent across other diverse cancers (n=85) in the cohort. 60% patients with sBRCA and HRR mutations treated with platinum / PARPi as NACT, achieved partial to pathological complete response (pCR) while 5 cases treated with IO are on follow up. Table: 421P
Prevalence of sBRCA and HRR genes across the multi-cancer cohort of 950 cases
Cancer | N=142 HRR+ve cases (%) | Major HRR alterations |
Gastrointestinal | 33 (23%) | ATM, ARID1A, BRCA1, PTEN, MRE11 |
Breast | 23 (16%) | BRCA1, PTEN, PALB2, ARID1A, ATM |
Triple-negative breast cancer (TNBC) | 13 (56% of Breast cancer cases with HRR alterations) | BRCA1, BRCA2, PTEN, BAP1, PALB2 |
Female genital tract | 20 (14%) | BRCA1, ARID1A, PTEN, RAD54L |
Lung | 19 (13%) | PTEN, ATM, BRCA1, ARID1A |
Head & neck | 13 (9%) | PTEN, ARID1A, ATM, BARD1, RAD50 |
Sarcoma | 10 (7%) | ATRX, PTEN, BRCA2, PALB2 |
Genitourinary | 10 (7%) | CDK12, BRCA1, PTEN |
Other cancers | 9 (6%) | PTEN, ARID1A, BAP1, RAD50 |
Carcinoma of unknown origin | 5 (4%) | ARID1A, ATRX, PTEN |
Conclusions
CGP identified sBRCA and HRR mutations in wide spectrum of cancers enabling the utility of PARPi as maintenance therapy, hence necessitating sBRCA and HRR testing as standard of care besides germline testing for personalized therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract